What is ABEO's current stock price?

ABEO (Abeona Therapeutics Inc.) is currently trading at $5.44 with a market cap of $310.1M.

What sector is Abeona Therapeutics Inc. in?

Abeona Therapeutics Inc. (ABEO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ABEO a good stock to buy?

Analysts have a Buy consensus on ABEO with a price target of $17.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ABEO Abeona Therapeutics Inc.

Healthcare

$5.44-1.45%ClosedMarket Cap: $310.1M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

3.94

PEG

0.02

P/B

2.13

P/S

21.32

EV/EBITDA

4.08

DCF Value

$0.80

FCF Yield

-27.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

51.9%

Operating Margin

-637.9%

Net Margin

454.9%

ROE

41.4%

ROA

33.3%

ROIC

-50.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$8.7M	$-17.1M	$—
Q4 null	$5.4M	$-20.5M	$—
FY null	$5.8M	$71.2M	$—
Q3 null	$0.00	$-5.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$17.00

Target (Median)

$17.00

Target Range

$17.00 - $17.00

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-19

HC Wainwright & Co.Buy

2025-10-13

HC Wainwright & Co.Buy

2025-08-18

OppenheimerOutperform

2025-08-15

HC Wainwright & Co.Buy

2025-07-16

Trading Activity

Insider Trades

View All

Alvino Markdirector

SellFri May 22

Crombez Ericdirector

SellFri May 15

Vasanthavada Madhavofficer: Chief Commercial Officer

SellMon May 11

Goldan Keith A.director

SellTue Apr 07

Goldan Keith A.director:

SellTue Apr 07

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.34

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Peers